Q1: 2026-05-05 Earnings Summary

EPS of -$1.54 misses by $0.08

|

Revenue of

$136.00M

(-2.36% Y/Y)

misses by $22.41M

Ultragenyx Pharmaceutical Inc. ( RARE ) Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDT

Company Participants

Howard Horn - Executive VP of Corporate Strategy & CFO

Joshua Higa - Director of Investor Relations & Corporate Communications

Presentation

Unknown Analyst

I'm one of the biotech analysts here at BofA. Our next presenting company is Ultragenyx. And here with me are Howard Horn, Chief Financial Officer; and Josh Higa, Head of IR. Thank you for joining us, guys.

Question-and-Answer Session

Unknown Analyst

So I think there's a lot going on at the company. I think most people are familiar with it, but maybe we can start with a quick overview of the company, kind of your commercial products, and you have a very busy second half of the year.…